pH-sensitive pluronic micelles combined with oxidative stress amplification for enhancing multidrug resistance breast cancer therapy

Cheng, Xu; Zeng, Xiaoli; Zheng, Yan; Qin, Fang; Wang, Xin; Wang, Jun

doi:10.1016/j.jcis.2020.01.029

Cited by 31 publications

(14 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 However, it still suffers from undesirable side effects, such as systemic toxicity, short half-life and lack of precise targets. [3][4][5] Especially, the occurrence of multidrug resistance (MDR) of cancer cells can reduce the efficacy of chemotherapeutic drugs, 6,7 which has become the most crucial reason for the failure of HCC treatment. The phenomenon was mainly attributed to the over-expression of ATPbinding cassette (ABC) transporter family in cancer cells, including ABCG1, ABCC1 and ABCG2.…”

Section: Introductionmentioning

confidence: 99%

Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment

Liang¹,

Wang²,

Shi³

et al. 2021

IJN

View full text Add to dashboard Cite

Background: Multidrug resistance (MDR) has emerged to be a major hindrance in cancer therapy, which contributes to the reduced sensitivity of cancer cells toward chemotherapeutic drugs mainly owing to the over-expression of drug efflux transporters. The combination of gene therapy and chemotherapy has been considered as a potential approach to improve the anti-cancer efficacy by reversing the MDR effect. Materials and Methods: The AS1411 aptamer-functionalized micelles were constructed through an emulsion/solvent evaporation strategy for the simultaneous co-delivery of doxorubicin and miR-519c. The therapeutic efficacy and related mechanism of micelles were explored based on the in vitro and in vivo active targeting ability and the suppression of MDR, using hepatocellular carcinoma cell line HepG2 as a model. Results:The micelle was demonstrated to possess favorable cellular uptake and tumor penetration ability by specifically recognizing the nucleolin in an AS1411 aptamerdependent manner. Further, the intracellular accumulation of doxorubicin was significantly improved due to the suppression of ABCG2-mediated drug efflux by miR-519c, resulting in the efficient inhibition of tumor growth. Conclusion:The micelle-mediated co-delivery of doxorubicin and miR-519c provided a promising strategy to obtain ideal anti-cancer efficacy through the active targeting function and the reversion of MDR.

show abstract

Section: Introductionmentioning

confidence: 99%

Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment

Liang¹,

Wang²,

Shi³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…The micellar system contained α-tocopheryl succinate, which is known to generate reactive oxygen species (ROS) in cancer cells. DOX-loaded POT micelles possessed highest drug accumulation and the strongest tumor growth inhibition in breast cancer induced mice [ 245 ]. In addition, the micelles could induce higher percentage of apoptosis at the tumor site without damage to healthy tissues and reduced breast cancer metastasis in vivo [ 245 ].…”

Section: Nanomedicine To Overcome Drug Resistance In Breast Cancermentioning

confidence: 99%

“…DOX-loaded POT micelles possessed highest drug accumulation and the strongest tumor growth inhibition in breast cancer induced mice [ 245 ]. In addition, the micelles could induce higher percentage of apoptosis at the tumor site without damage to healthy tissues and reduced breast cancer metastasis in vivo [ 245 ]. Cheng et al observed similar results in NPs co-delivering DOX and pyrrolidinedithiocarbamate (PDTC).…”

Section: Nanomedicine To Overcome Drug Resistance In Breast Cancermentioning

confidence: 99%

Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue

Gote

Nookala

Bolla

et al. 2021

IJMS

View full text Add to dashboard Cite

Breast cancer, specifically metastatic breast, is a leading cause of morbidity and mortality in women. This is mainly due to relapse and reoccurrence of tumor. The primary reason for cancer relapse is the development of multidrug resistance (MDR) hampering the treatment and prognosis. MDR can occur due to a multitude of molecular events, including increased expression of efflux transporters such as P-gp, BCRP, or MRP1; epithelial to mesenchymal transition; and resistance development in breast cancer stem cells. Excessive dose dumping in chemotherapy can cause intrinsic anti-cancer MDR to appear prior to chemotherapy and after the treatment. Hence, novel targeted nanomedicines encapsulating chemotherapeutics and gene therapy products may assist to overcome cancer drug resistance. Targeted nanomedicines offer innovative strategies to overcome the limitations of conventional chemotherapy while permitting enhanced selectivity to cancer cells. Targeted nanotheranostics permit targeted drug release, precise breast cancer diagnosis, and importantly, the ability to overcome MDR. The article discusses various nanomedicines designed to selectively target breast cancer, triple negative breast cancer, and breast cancer stem cells. In addition, the review discusses recent approaches, including combination nanoparticles (NPs), theranostic NPs, and stimuli sensitive or “smart” NPs. Recent innovations in microRNA NPs and personalized medicine NPs are also discussed. Future perspective research for complex targeted and multi-stage responsive nanomedicines for metastatic breast cancer is discussed.

show abstract

“…Cheng, et al [92] designed a new type of pH-sensitive pluronic micelle that can not only be used for oxidative therapy, but can also reverse the synergistic effects of MDR, which hinders cancer treatment (Figure 22). Through the acid-labile orthoester (OE) bond, the orthoester in particular has better biocompatibility and stability.…”

Section: Pluronics With Hlb < 20 and Po Chain > 60mentioning

confidence: 99%

Polymeric Drug Delivery System Based on Pluronics for Cancer Treatment

Qiu

Yin

et al. 2021

Molecules

View full text Add to dashboard Cite

Pluronic polymers (pluronics) are a unique class of synthetic triblock copolymers containing hydrophobic polypropylene oxide (PPO) and hydrophilic polyethylene oxide (PEO) arranged in the PEO-PPO-PEO manner. Due to their excellent biocompatibility and amphiphilic properties, pluronics are an ideal and promising biological material, which is widely used in drug delivery, disease diagnosis, and treatment, among other applications. Through self-assembly or in combination with other materials, pluronics can form nano carriers with different morphologies, representing a kind of multifunctional pharmaceutical excipients. In recent years, the utilization of pluronic-based multi-functional drug carriers in tumor treatment has become widespread, and various responsive drug carriers are designed according to the characteristics of the tumor microenvironment, resulting in major progress in tumor therapy. This review introduces the specific role of pluronic-based polymer drug delivery systems in tumor therapy, focusing on their physical and chemical properties as well as the design aspects of pluronic polymers. Finally, using newer literature reports, this review provides insights into the future potential and challenges posed by different pluronic-based polymer drug delivery systems in tumor therapy.

show abstract

pH-sensitive pluronic micelles combined with oxidative stress amplification for enhancing multidrug resistance breast cancer therapy

Cited by 31 publications

References 62 publications

Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment

Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment

Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue

Polymeric Drug Delivery System Based on Pluronics for Cancer Treatment

Contact Info

Product

Resources

About